Cargando…
Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583953/ https://www.ncbi.nlm.nih.gov/pubmed/36284665 http://dx.doi.org/10.1002/trc2.12361 |
| _version_ | 1784813182976524288 |
|---|---|
| author | Petersen, Ronald C. Graf, Ana Carrillo, Maria C. Weber, Christopher J. |
| author_facet | Petersen, Ronald C. Graf, Ana Carrillo, Maria C. Weber, Christopher J. |
| author_sort | Petersen, Ronald C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9583953 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95839532022-10-24 Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints Petersen, Ronald C. Graf, Ana Carrillo, Maria C. Weber, Christopher J. Alzheimers Dement (N Y) News John Wiley and Sons Inc. 2022-10-20 /pmc/articles/PMC9583953/ /pubmed/36284665 http://dx.doi.org/10.1002/trc2.12361 Text en © 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | News Petersen, Ronald C. Graf, Ana Carrillo, Maria C. Weber, Christopher J. Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_full | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_fullStr | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_full_unstemmed | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_short | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_sort | current understanding of ad pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| topic | News |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583953/ https://www.ncbi.nlm.nih.gov/pubmed/36284665 http://dx.doi.org/10.1002/trc2.12361 |
| work_keys_str_mv | AT petersenronaldc currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT grafana currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT carrillomariac currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT weberchristopherj currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints |